Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214655 · ClinicalTrials.gov registry record · Phase 1
A Study for Patients With Acute Leukemia
A Phase 1 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
NCT01214655 is a Phase 1 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 33 participants.
The verdict
NCT01214655, a Phase 1 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
Study Summary
This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants with acute leukemia. Part A and Part B are dose escalation of two schedules in participants with acute leukemia. Parts A and B will enroll concurrently. Part C is a dose expansion for each schedule in participants with acute myeloblastic leukemia (AML).
Interventions
- DRUG LY2523355
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214655
The ClinicalTrials.gov registry entry for NCT01214655 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2523355 is the first listed.
NCT01214655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214655 about?
NCT01214655 is a clinical study titled "A Study for Patients With Acute Leukemia". This study is a multicenter, nonrandomized, open-label, dose-escalation with intra-patient dose-escalation, Phase 1 study of intravenous LY2523355 to determine the dose of LY2523355 that can be safely administered to participants with acute leukemia. Part A and Part B are dose escalation of two sche...
What is the current status of trial NCT01214655?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2008-06. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01214655?
The interventions under investigation include: LY2523355 (DRUG).
Who is sponsoring clinical trial NCT01214655?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.